Open AccessProviding Oncology Pharmacy Services During the Coronavirus Pandemic: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique [SFPO]) Guidelines
Author(s) -
Bertrand Pourroy,
Jean Francois Tournamille,
Christophe Bardin,
Florian Slimano,
R. Chevrier,
Catherine Rioufol,
Isabelle Madelaine
Publication year - 2020
Publication title -
jco oncology practice
Language(s) - English
Resource type - Journals
eISSN - 2688-1535
pISSN - 2688-1527
DOI - 10.1200/op.20.00295
Subject(s) - pharmacy , pandemic , medicine , covid-19 , pharmaceutical care , pharmacy practice , family medicine , oncology , infectious disease (medical specialty) , disease
PURPOSE: Patients with cancer are at higher risk for contracting the COVID-19 infection and are more likely to have higher morbidity and mortality. This is a big challenge for oncology teams that have to treat patients to avoid contamination by SARS-CoV-2. The aim of the current work is to present oncology pharmacy practice guidelines during the COVID-19 pandemic to secure the pharmaceutical care of patients with cancer.METHODS: The bureau of the French Society for Oncology Pharmacy proposed these recommendations according to the French High Authority of Health following the Guidelines of Good Practice, slightly modified according to the pandemic crisis situation. These guidelines were developed by a working group of 7 experts in oncology pharmacy practice. Furthermore, the guidelines were assessed by 31 independent reviewers.RESULTS: One hundred percent of reviewers approved the guidelines and 90% of them suggested some improvements. The final version incorporates the best comments and consists of 26 recommendations organized in 8 different sections.CONCLUSION: These guidelines allow secure pharmaceutical management of patients with cancer during the COVID-19 pandemic.